Close Menu

NEW YORK — Vermillion today priced its public offering of 18.75 million shares of its common stock at $.80 per share.

The Austin, Texas-based cancer diagnostics company has granted the underwriter of the offering a 30-day option to purchase up to an additional 2.8 million shares of its common stock at $.80 per share. Gross proceeds are expected to be $15 million, or $17.25 million if the underwriter exercises its option to purchase additional shares in full.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.